&Partners’s Takeda Pharmaceutical TAK Stock Holding History

&Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$606K	Buy	37,853 +4,754	+14%	+$78.7K	﹤0.01%	1722
2026 Q1	$613K	Buy	33,099 +4,470	+16%	+$78.5K	﹤0.01%	1585
2025 Q4	$446K	Buy	28,629 +2,554	+10%	+$36.5K	﹤0.01%	1679
2025 Q3	$382K	Buy	26,075 +4,877	+23%	+$72.4K	﹤0.01%	1621
2025 Q2	$331K	Buy	21,198 +2,749	+15%	+$40.6K	﹤0.01%	1571
2025 Q1	$278K	Sell	18,449 -5,353	-22%	-$75K	﹤0.01%	1444
2024 Q4	$317K	Buy	23,802 +7,055	+42%	+$96.9K	﹤0.01%	1307
2024 Q3	$238K	Buy	16,747 +5,351	+47%	+$75.9K	﹤0.01%	1217
2024 Q2	$147K	Buy	11,396 +319	+3%	+$4.22K	0.01%	866
2024 Q1	$154K	Buy	+11,077	New	+$161K	0.02%	467

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

&Partners's TAK Position: Q2 2026 in Review

&Partners increased its Takeda Pharmaceutical (TAK) stake by 14% in Q2 2026, buying an estimated $78.7K and bringing the position to 37,853 shares worth $606K. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

&Partners first reported a position in TAK in Q1 2024 and has held it in 10 quarters since. The position peaked at $613K in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

&Partners held 37,853 shares of Takeda Pharmaceutical worth $606K as of Q2 2026.
&Partners bought 4,754 Takeda Pharmaceutical shares in Q2 2026, an estimated $78.7K.
Takeda Pharmaceutical made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1722 holding.
&Partners first reported a position in Takeda Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
&Partners's Takeda Pharmaceutical position peaked at $613K in Q1 2026.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.